TPIDB > 臨床試驗主持人
臨床試驗主持人
更新時間：2023-09-19
盧彥伸LU, YEN-SHEN
- 計畫主持人
- 執行臨床試驗年資 22 年 9 個月
發表文獻
26筆
1
Lu YS, Lee KS, Chao TY, Tseng LM, Chitapanarux I, Chen SC, Liu CT, Sohn J, Kim JH, Chang YC, Yang Y, Shotelersuk K, Jung KH, Valenti R, Slader C, Gao M, Park YH. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. Clin Cancer Res. 2021 Jan 15;27(2):408-417. doi: 10.1158/1078-0432.CCR-20-1008. Epub 2020 Jul 27. PMID: 32718997.
2
Schmid P, Sablin MP, Bergh J, Im SA, Lu YS, Martínez N, Neven P, Lee KS, Morales S, Pérez-Fidalgo JA, Adamson D, Gonçalves A, Prat A, Jerusalem G, Schlieker L, Espadero RM, Bogenrieder T, Huang DC, Crown J, Cortés J. A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. Breast Cancer Res. 2021 Jan 15;23(1):8. doi: 10.1186/s13058-020-01382-8. PMID: 33451345; PMCID: PMC7811234.
3
André F, Ciruelos EM, Juric D, Loibl S, Campone M, Mayer IA, Rubovszky G, Yamashita T, Kaufman B, Lu YS, Inoue K, Pápai Z, Takahashi M, Ghaznawi F, Mills D, Kaper M, Miller M, Conte PF, Iwata H, Rugo HS. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Ann Oncol. 2021 Feb;32(2):208-217. doi: 10.1016/j.annonc.2020.11.011. Epub 2020 Nov 25. PMID: 33246021.
4
Tolaney SM, Im YH, Calvo E, Lu YS, Hamilton E, Forero-Torres A, Bachelot T, Maur M, Fasolo A, Tiedt R, Nardi L, Stammberger U, Abdelhady AM, Ruan S, Lee SC. Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. Clin Cancer Res. 2021 Jan 15;27(2):418-428. doi: 10.1158/1078-0432.CCR-20-0645. Epub 2020 Sep 4. PMID: 32887722.
5
Saura C, Oliveira M, Feng YH, Dai MS, Chen SW, Hurvitz SA, Kim SB, Moy B, Delaloge S, Gradishar W, Masuda N, Palacova M, Trudeau ME, Mattson J, Yap YS, Hou MF, De Laurentiis M, Yeh YM, Chang HT, Yau T, Wildiers H, Haley B, Fagnani D, Lu YS, Crown J, Lin J, Takahashi M, Takano T, Yamaguchi M, Fujii T, Yao B, Bebchuk J, Keyvanjah K, Bryce R, Brufsky A; NALA Investigators. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial. J Clin Oncol. 2020 Sep 20;38(27):3138-3149. doi: 10.1200/JCO.20.00147. Epub 2020 Jul 17. PMID: 32678716; PMCID: PMC7499616.
6
Lien HC, Lee YH, Chen IC, Lin CH, Chen TW, Lu YT, Lu YS. Tumor-infiltrating lymphocyte abundance and programmed death-ligand 1 expression in metaplastic breast carcinoma: implications for distinct immune microenvironments in different metaplastic components. Virchows Arch. 2021 Apr;478(4):669-678. doi: 10.1007/s00428-020-02954-x. Epub 2020 Oct 21. PMID: 33089401.
7
Lin CH, Yap YS, Lee KH, Yeo W, Ueno T, Li H, Huang SM, Lu YS. Response to Sung, Rosenberg, and Yang. J Natl Cancer Inst. 2020 May 1;112(5):547-548. doi: 10.1093/jnci/djz191. PMID: 31545369; PMCID: PMC7225667.
8
Kuo CT, Chen CL, Li CC, Huang GS, Ma WY, Hsu WF, Lin CH, Lu YS, Wo AM. Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models. Sci Rep. 2019 Jul 29;9(1):10898. doi: 10.1038/s41598-019-45319-4. Erratum in: Sci Rep. 2020 Aug 19;10(1):14139. PMID: 31358767; PMCID: PMC6662705.
9
Chuang SC, Lin CH, Lu YS, Hsiung CA. Mortality of Pregnancy Following Breast Cancer Diagnoses in Taiwanese Women. Oncologist. 2020 Feb;25(2):e252-e258. doi: 10.1634/theoncologist.2019-0451. Epub 2019 Nov 25. PMID: 32043784; PMCID: PMC7011637.
10
Chen CH, Lu YS, Cheng AL, Huang CS, Kuo WH, Wang MY, Chao M, Chen IC, Kuo CW, Lu TP, Lin CH. Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist. 2020 Jan;25(1):e16-e23. doi: 10.1634/theoncologist.2019-0123. Epub 2019 Aug 1. PMID: 31371522; PMCID: PMC6964121.
